Radiopharmaceuticals Are Driving Innovation in Oncology Drug Development
Radiopharmaceuticals Are Driving Innovation in Oncology Drug Development
12 PagesThis white paper examines how radiopharmaceutical therapies are advancing precision oncology by delivering radioactive isotopes directly to tumor cells while limiting damage to healthy tissue. These treatments link a radionuclide to a molecule that binds a specific cancer target, enabling both diagnostic imaging and therapy through a theranostic approach. Recent clinical successes and approvals of lutetium-177 therapies for neuroendocrine tumors and prostate cancer have increased development momentum. The paper highlights the value of target-based patient selection, image-guided treatment, and improved progression-free survival.
